For the treatment of idiopathic interstitial pneumonia. Idiopathic interstitial pneumonia is a rare disease with unknown etiology and similar clinical characteristics. In 2017, there were about 200,000 cases worldwide, 37,000 in the United States and 57,000 in China. Although idiopathic interstitial pneumonia is histologically divided into six subgroups, all are characterized by varying degrees of inflammation and fibrosis, and all cause dyspnea and typical radiographic abnormalities. There is currently no effective treatment for idiopathic interstitial pneumonia on the market, and patients can only rely on extensive use of glucocorticoids as an alternative therapy to stay alive. Long-term glucocorticoid therapy not only has uncertain efficacy, but also can cause a series of side effects. Patients often end up needing lung transplants to save their lives. EG-001 has highly selective immunomodulatory and anti-inflammatory effects, and can enhance glucocorticoid sensitivity. Animal experiments show that EG-001 can inhibit lung inflammation, significantly inhibit pulmonary fibrosis and improve lung function. The global idiopathic interstitial pneumonia market is estimated to exceed US$4 billion.
EG-009 is an oral drug for the treatment of cytokine storm caused by SARS-CoV-2 infection. Cytokine storm is a complex inflammatory response that is one of the major causes of death in COVID-19 patients. Cytokine storm occurs when levels of multiple cytokines are significantly elevated, eventually leading to acute respiratory distress syndrome and multiple organ failure. Cytokine storm can be caused not only by viral infections, but also after organ transplantation, macromolecular drug therapy, and CAR-T cell therapy. EG-009 will mainly be used to treat cytokine storm in hospitalized COVID-19 patients, while EG-009 oral formulation will be used to prevent and treat secondary cytokine storm in post-discharge COVID-19 patients. According to the latest statistics from the World Health Organization, more than 200 million people worldwide has been infected and 4.5 million has died by September 2021, so the development of a drug to treat COVID-19 is urgent.
EG-009A is an injection for the treatment of cytokine storms caused by moderate to severe coronavirus pneumonia. Cytokine storm is a complex inflammatory response that is one of the major causes of death in COVID-19 patients. Cytokine storm occurs when levels of multiple cytokines are significantly elevated, eventually leading to acute respiratory distress syndrome and multiple organ failure. Cytokine storms can be caused not only by viral infections, but also after organ transplantation, macromolecular drug therapy, and CAR T cell therapy. EG-009A injection will mainly be used to treat cytokine storms in hospitalized COVID-19 patients. According to the latest statistics from the World Health Organization, more than 200 million people worldwide will be infected and 4.5 million will die by September 2021, so the development of a drug to treat COVID-19 is urgent.
EG-007 is an injectable drug used to treat endometrial cancer. Endometrial cancer is an epithelial malignant tumor occurring in the endometrium and is one of the three malignant tumors of female reproductive system. In 2020, there were about 420,000 new cases in the world, including about 80,000 cases in China and 60,000 cases in the United States. Endometrial cancer ranked first among female reproductive system tumors in the United States. Although immunotherapy drugs account for more than 60% of clinical trials in endometrial cancer, the low response rate of immune checkpoint drugs is an urgent problem to be solved in clinical practice. Animal experiments showed that EG-007 could enhance the therapeutic effect of anti-PD-1 /L1 antibody, which was related to enhancing the infiltration of CD8+ T cells, up-regulating IFN-γ signaling pathway, and improving the immunosuppressive microenvironment in tumor tissues. Our goal is to develop EG-007 in combination with immunotherapy as a first-line treatment for advanced endometrial cancer.
EG-101 is an injectable drug used to treat preeclampsia. Preeclampsia, which affects 2% to 7% of pregnancies in developed countries, is a major clinical complication of maternal and infant mortality. It is characterized by hypertension, proteinuria, and damage to other organs, most commonly the liver and kidneys. The specific pathogenesis of preeclampsia is still unclear, and may be related to vascular endothelial dysfunction. There are currently no approved drugs on the market for the treatment and prevention of pre-eclampsia. EG-101 has shown good therapeutic effects in animal models of preeclampsia, with significant improvement in hypertension and proteinuria.
EG-201 is an eye drop for the treatment of age-related macular degeneration. Data show that wet macular degeneration is responsible for 90% of age-related macular blindness, and switching to wet macular degeneration can lead to central vision loss within 10-14 days. The current treatment is to inject anti-VEGF drugs into the eyeball, but there is often a risk of side effects, and currently the use of intravitreal injection of large-molecule drugs is very expensive. Therefore, the market needs locally used small molecule eye drops with novel mechanisms to supplement or replace existing large molecule intravitreal injection drugs. EG-201 is an eye drop with a new chemical structure and a new mechanism of action. Animal experiments have also proved its therapeutic effect on wet macular degeneration.
EG-301 is used to treat patients over 50 years of age with dry macular disease. EG-301 will be an oral dosage form that has been shown to be effective and safe in animal studies with fewer side effects. In 2020, there were about 100 million patients with macular disease worldwide, of which dry macular disease accounted for about 90%. There is an absolute global clinical need for dry macular disease. There are currently no drugs on the market to treat this disease, and the market size of its drugs is about US$60 - 90 billion.
Focal segmental glomerulosclerosis (FSGS) is a disease in which scar tissue develops on the parts of the kidneys that filter waste from the blood (glomeruli). FSGS may cause non-specific signs and symptoms, including protein in the urine, elevated levels of creatinine, and swelling. FSGS is a serious condition that can lead to kidney failure, for which the only treatment options are dialysis or kidney transplant. It is estimated that the incidence of FSGS is between 1.4 and 21 cases per million population, about 7-10% of children and 20-30% of adult patients with nephrotic syndrome. FSGS is more common in adult males, and its incidence is 1.5- 2 times that of females. In the United States, about 40,000 people suffer from FSGS, and more than 5,400 people are diagnosed with FSGS every year.
Diabetic retinopathy (DR) is a microvascular disorder occurring due to long term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. It is estimated that 4.1 million people aged 40 and over in the United States suffer from diabetic retinopathy, and one out of every 29 people suffers from this disease. In 2020, the global market value of diabetic retinopathy drugs will reach about 7.6 billion US dollars. It is estimated that the drug market will grow at a compound annual growth rate of 5.6% during 2021-2026.
Mild cognitive impairment (MCI) is a general term most commonly defined as a subtle but measurable memory disorder. MCI is characterized by ongoing memory problems but not by confusion, attention problems, or language difficulties. No medication has been approved for use in the treatment of MCI. This disease is common in the elderly population, The morbidity of 65-year-old population accounts for 1-2%, and that of 85-year-old population reaches about 30%. The market value of dementia drugs in 2020 is about $127 million, and it is estimated that the revenue will be about $196 million in 2026, with a compound annual growth rate of 7.87% in the forecast period.
Crohn's disease is a chronic intestinal inflammation of unknown etiology. Crohn's disease affected 4 million people worldwide in 2017, including about 1.69 million in the United States and 550,000 in China. The most common sites of Crohn's disease are the distal small intestine and the ascending colon. Common symptoms of the disease include chronic diarrhea, spastic abdominal pain, fever and weight loss. Crohn's disease can eventually cause intestinal obstruction, perforation of the intestine, abdominal abscesses, and fistulas. The current treatment for Crohn's disease is symptomatic treatment, including antidiarrheal, anti-inflammatory, immunomodulatory and surgical treatment. The biggest drawback of drug therapy is that only a small amount of the drug can reach the distal small intestine and ascending colon, where the disease is most common. EG-006 is a special double-capsule that can pass through the acidic stomach and the alkaline small intestine before disintegrating at the end of the small intestine. Thus, it concentrates the drug in the distal small intestine and ascending colon for optimal efficacy. The global Crohn's disease market was over US$10 billion in 2017.
An oral preparation for the treatment of steroid-resistant nephrotic syndrome in children. Pediatric nephrotic syndrome is a serious life-threatening disease in children. Currently, there is no drug to treat this kind of disease. The incidence is 2-4/100,000 in North America and about 10/100,000 in Asia. The main treatment for childhood nephropathy is glucocorticoid therapy, but 10% of children with nephrotic syndrome are glucocorticoid-resistant patients, and the existing conventional treatment for these patients is not effective. Our pharmacological experiments proved that EG-002 can effectively treat glucocorticoid-resistant nephrotic syndrome. At the same time, EG-002 not only has good compliance in children, but also has higher safety than glucocorticoids. The global market for childhood kidney disease is estimated at US$5.3 billion.
Asthma is one of the most common chronic diseases in the world at present. There are about 334 million people suffering from asthma worldwide, including about 25 million in the United States and 100 million in China. At present, the drugs used for asthma treatment are mainly anti-inflammatory drugs and bronchodilators. The primary role of respiratory anti-inflammatory drugs is to inhibit inflammation that causes airway narrowing (e.g., glucocorticoids, leukotriene modulators, and mast cell stabilizers). The main function of bronchodilators is to relax the airway smooth muscle (β -adrenergic receptor agonists, cholinergic receptor antagonists, etc.). Although there are many drugs available to treat asthma, many patients still do not respond to existing treatments. EG-005 is an inhalant that can inhibit inflammation of the respiratory tract, relax the smooth muscle of the respiratory tract and inhibit sputum secretion, thus achieving the effect of treating asthma. Global asthma is expected to reach US$25.7 billion in 2024.